31DEC

Welcome To MJPPS

The editors welcome the submission of relevant articles for editorial consideration. Manuscripts should be addressed to editor@medjpps.com.
Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
http://www.medjpps.periodikos.com.br/article/doi/10.5281/zenodo.18008693

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

REVIEW

Suzetrigine mechanism, efficacy, and clinical implications: A narrative review

Nada M. Shallof, Abduelmula R. Abduelkarem

http://dx.doi.org/10.5281/zenodo.18008693 Mediterr J Pharm Pharm Sci, Ahead of Print, 2025
PDF
PDF
Downloads: 0
Views: 69

Abstract

Acute pain, especially in postoperative and trauma areas, continues to be a substantial clinical problem all around the world, and this has been made worse by the opioid crisis as well as the drawbacks of the current non-opioid analgesics. The recent approval by the FDA of Suzetrigine (Journavx®) in January 2025 as the first-ever non-opioid analgesic aimed at the NaV1.8 sodium channel has opened new paths in pain management. Suzetrigine works only on NaV1.8 in the peripheral pain-sensing neurons, giving the patient targeted relief from pain without central nervous system (CNS) side effects or the risk of addiction. This paper sums up the newest clinical trial results (NAVIGATE-1 and NAVIGATE-2), real-world evidence, and regulatory frameworks to give a complete account of Suzetrigine’s pharmacology, clinical efficacy, safety profile, and potential to change acute pain treatment. While Suzetrigine showed a statistically significant and clinically relevant reduction in pain during Phase III trials, its use on a long-term basis for chronic pain and in other fields still has to be studied. This review furthermore evaluates the factors that make it difficult to approve such medicine, like doctors' education and the cost, and at the same time, it encourages the research and policy changes that will be needed to harness the full power of Suzetrigine.

Keywords

Acute pain, NaV1.8 inhibitor, non-narcotic analgesics, pain management, Suzetrigine

References

  1. International Association for the Study of Pain (IASP). IASP terminology. Available at: https://www.iasp-pain.org/ resources/terminology/ (Accessed: 24 November 2025).
  2. Cohen SP, Vase L, Hooten WM. Chronic pain: An update on burden, best practices, and new advances. Lancet. 2021; 397(10289): 2082-2097. doi: 10.1016/S0140-6736(21)00393-7
  3. U.S. Food and Drug Administration (FDA). FDA approves novel non-opioid treatment for moderate to severe acute pain. FDA News Release, 30 January 2025. Available at: https://www.fda.gov/news-events/press-announcements/ fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain (Accessed: 24 November 2025).
  4. Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, et al. Suzetrigine, a non-opioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025; 142(6): 1085-1099. doi: 10.1097/ALN.0000000000005460
  5. Centers for Disease Control and Prevention (CDC). Drug overdose deaths in the United States, 1999-2024. Available at: https://www.cdc.gov/nchs/products/databriefs/db457.htm (Accessed: 4 December 2025).
  6. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis: An expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine. 2015; 13(55): 1-22. doi: 10.1186/s12916-015-0285-8
  7. U.S. Food and Drug Administration (FDA). Development of non-opioid analgesics for acute pain; Draft guidance for industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ development-non-opioid-analgesics-acute-pain-draft-guidance-industry (Accessed: 24 November 2025).
  8. International Association for the Study of Pain (IASP). FDA approves non-opioid treatment for moderate to severe acute pain. IASP News. Available at: https://www.iasp-pain.org/publications/iasp-news/fda-approves-non-opioid-treatment-for-moderate-to-severe-acute-pain/ (Accessed: 24 November 2025).
  9. Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain and Therapy. 2025; 14(2): 655-674. doi: 10.1007/s40122-024-00697-0
  10. Stewart RG, Osorno T, Fujita A, Jo S, Ferraiuolo A, Carlin K, Bean BP. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proceedings of the National Academy of Sciences of the United States of America. 2025; 122 (22): e2503570122. doi: 10.1073/pnas.2503570122
  11. Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiological Reviews. 2022; 102(3): 1271-1303. doi: 10.1152/physrev.00052.2020
  12. Chen R, Liu Y, Qian L, Yi M, Yin H, Wang S, Xiang B. Sodium channels as a new target for pain treatment. Frontiers in Pharmacology. 2025; 16: 1573254. doi: 10.3389/fphar.2025.1573254
  13. Vaelli P, Fujita A, Jo S, Zhang HB, Osorno T, Ma X, Bean BP. State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548. Molecular Pharmacology. 2024; 106(6): 298-308. doi: 10.1124/molpharm.124. 000745
  14. Xie YF. Nav1.8 and chronic pain: from laboratory animals to clinical patients. Biomolecules. 2025; 15(5): 694. doi: 10.3390/biom15050694
  15. Felix R, Corzo-Lopez A, Sandoval A. Voltage-gated ion channels in neuropathic pain signaling. Life (Basel). 2025; 15(6): 888. doi: 10.3390/life15060888
  16. Institute for Clinical and Economic Review (ICER). Suzetrigine for acute pain: effectiveness and value. 2025. Available at: https://icer.org/wp-content/uploads/2025/02/ICER_Acute-Pain_Evidence-Report_For-Publication_ 020525.pdf (Accessed: 24 November 2025).
  17. McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, et al. Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study. Journal of Pain Research. 2025; 18: 1569-1576. doi: 10.2147/JPR.S509144
  18. US Pharmacist. Novel nonopioid analgesic for acute pain. 2025. Available at: https://www.uspharmacist.com/ article/novel-nonopioid-analgesic-for-acute-pain (Accessed: 24 November 2025).
  19. Vertex Pharmaceuticals Incorporated. JOURNAVX (suzetrigine) tablets, for oral use [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2025. Available at: https://www.journavxhcp.com/ (Accessed: 24 November 2025).
  20. Fine PG. Equity in pain management: Addressing disparities in access to non-opioid therapies. Journal of Pain and Symptom Management. 2023; 65(2): e89-e95. doi: 10.1016/j.jpainsymman.2022.10.012
  21. Evans FM, Wake PB, Gathuya ZN, McDougall RJ. Access to safe pediatric anesthesia in LMICs-The problem is clear; It is time to solve it! Anesthesia and Analgesia. 2022; 134(4): 724-727. doi: 10.1213/ANE.000000000000 5924
  22. Staatz CE, Goodman LK, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical Pharmacokinetics. 2021; 60(4): 413-435. doi: 10.1007/s40262-020-00984-1
  23. U.S. Food and Drug Administration (FDA). Development of non-opioid analgesics for chronic pain; Draft guidance for industry. Fed. Regi. 2025. Available at: https://www.federalregister.gov/documents/2025/09/11/2025-17442/ development-of-non-opioid-analgesics-for-chronic-pain-draft-guidance-for-industry-availability (Access: 24 Nov. 2025).
  24. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonized Guidelines. Available at https://www.ich.org/page/multidisciplinary-guidelines (Accessed: 4 Dec. 2025).
  25. European Medicines Agency (EMA). Guideline on the development of medicinal products for the treatment of pain. Available at: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema _group types/0000000000000190 (Accessed: 24 November 2025).

Submitted date:
10/14/2025

Reviewed date:
12/14/2025

Accepted date:
12/20/2025

Publication date:
12/21/2025

69480822a95395196a01d7ba medjpps Articles
Links & Downloads
2789-1895 (Electronic) 2958-3101 (Printed)
Mediterr J Pharm Pharm Sci ©2025 All rights reserved.

Mediterr J Pharm Pharm Sci

Share this page
Page Sections